Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10488677 | 0.87 | GAA (0.77) | GAALMNAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL10488561 | 0.87 | GAA (0.77) | GAALMNAMAPTALDH1A1KDM4E | |
| SCHEMBL11542705 | 0.84 | GAA (0.73) | GAALMNAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL11136337 | 0.81 | GAA (0.68) | GAALMNAMAPTALDH1A1SMN1; SMN2 | |
| Alcohol SCHEMBL16401346 | 0.81 | GAA (0.68) | GAALMNAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL11735902 | 0.80 | GAA (0.67) | GAAMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL9037897 | 0.79 | GAA (0.66) | GAAALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL8421167 | 0.79 | GAA (0.65) | GAALMNAMAPTALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9004815 | 0.78 | GAA (0.64) | GAAALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL8910582 | 0.77 | GAA (0.62) | GAALMNAMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2012-05-31 | — | — | US | claimed |
| CN-105886476-B | Compositions and methods for enhancing viral potency | 渥太华医院研究所 | 2020-02-18 | — | — | CN | disclosed |
| EP-2451795-B1 | COMPOSITIONS AND USES FOR ENHANCING VIRUS PRODUCTION | OTTAWA HOSPITAL RES INST (CA) | 2016-07-13 | — | — | EP | disclosed |
| EP-2451795-B1 | COMPOSITIONS AND USES FOR ENHANCING VIRUS PRODUCTION | OTTAWA HOSPITAL RES INST (CA) | 2016-07-13 | — | — | EP | disclosed |
| US-9283254-B2 | Compositions and methods for enhancing virus efficacy | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2016-03-15 | — | — | US | disclosed |
| US-20150202240-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-07-23 | — | — | US | disclosed |
| US-20150202240-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-07-23 | — | — | US | disclosed |
| US-8940291-B2 | Compositions and methods for enhancing virus efficacy | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-01-27 | — | — | US | disclosed |
| US-8940291-B2 | Compositions and methods for enhancing virus efficacy | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-01-27 | — | — | US | disclosed |
| US-8940291-B2 | Compositions and methods for enhancing virus efficacy | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-01-27 | — | — | US | disclosed |
| CN-102532126-A | 2-substituted-4-chloro-5-[5-subtsituted amino-2-(1,3,4-thiadiazole)-sulfydryl]-3(2H)- pyridazinone derivatives, and preparation method and application thereof | UNIV GUIZHOU | 2012-07-04 | — | — | CN | disclosed |
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2012-05-31 | — | — | US | disclosed |
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2012-05-31 | — | — | US | disclosed |
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2012-05-31 | — | — | US | disclosed |
| WO-2011003191-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2011-01-13 | — | — | WO | disclosed |
| US-4871737-A | 3-Amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants muscle relaxants and anxiolytics | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0315433-A2 | 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics | A.H. ROBINS COMPANY, INCORPORATED (US) | 1989-05-10 | — | — | EP | disclosed |
| US-4826866-A | 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | HAVCR2, MAVS, TSG101 | GAA 677/4885LMNA 1828/4885MAPT 3295/4885 |
| US-20150202240-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | HAVCR2, MAVS, TSG101 | GAA 677/4885LMNA 1828/4885MAPT 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.